Intuitive Surgical is a pioneering medical device company specializing in robotic-assisted surgical systems, most notably the da Vinci Surgical System. This innovative platform enhances the precision and control of minimally invasive surgical procedures, enabling surgeons to perform operations with greater accuracy and reduced recovery times for patients. The company is dedicated to advancing the field of robotics in surgery, providing training and support for healthcare professionals, and continually innovating its technology to improve patient outcomes across various medical specialties. Read More
Intuitive Surgical Inc. (NASDAQ: ISRG) announces Dave Rosa as next CEO, effective July 1, 2025. Long-serving CEO Gary Guthart to become executive chair.
President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive’s boardCurrent Board Chair Craig Barratt to become lead independent director
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital.
The select few that can do all three for many years are often the ones that make you life-changing money.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Teleflex (NYSE:TFX) and its peers.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP’s capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorectal excision, colectomy, abdominoperineal resection, and sigmoidectomy.
Despite beating on the top and bottom lines, tariff uncertainty makes the outlook for ISRG stock fluid; investors may want to wait for clarity before jumping in
